Cadila Healthcare is currently trading at Rs. 236.50, up by 8.30 points or 3.64% from its previous closing of Rs. 228.20 on the BSE.
The scrip opened at Rs. 229.00 and has touched a high and low of Rs. 237.25 and Rs. 226.00 respectively. So far 31934 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 387.50 on 10-Oct-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 237.50 and Rs. 224.30 respectively. The current market cap of the company is Rs. 24124.49 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride Tablets, (US RLD - Welchol), 625 mg. This medication is used along with a proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in the blood. Lowering cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group now has 273 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.